Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System
ORL · 2023
DOI: 10.1159/000534545 ↗Kurz gefasst
Fachartikel in der Zeitschrift ORL, 2023. Verfasst von Taylor J Stack und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery at the University of North Carolina, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Anaphylaxis, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
Over the last 3 years, the FDA has approved dupilumab, omalizumab, and mepolizumab for the treatment of CRSwNP; however, adverse events of these biologics have not been described in post-marketing surveillance trials. By utilizing the FDA Adverse Event Reporting System (FAERS), this study describes and compares biologic-associated adverse events in T2 disease.
Methods
This case-non-case study assessed disproportionate reporting rates using reporting odds ratios (RORs). RORs and p values for biologic-associated AEs were categorized and compared among dupilumab, omalizumab, and mepolizumab. This analysis included AEs associated with all treatment indications. Relative AE rates and outcomes were calculated.
Results
There were a total of 112,560, 24,428, and 18,741 unique AE reports associated with dupilumab, omalizumab, and mepolizumab, respectively. Omalizumab had the strongest association with anaphylaxis (ROR = 20.80, 95% confidence interval [CI]: 18.58, 23.29). Dupilumab had large relative proportions and positive signals in the ophthalmologic category (7.76%, ROR = 6.20, 95% CI: 6.06, 6.35), such as with blurry vision (ROR = 3.80, CI: 3.52, 4.12) and visual impairment (ROR = 1.98, CI: 1.80, 2.19). Dupilumab was the only biologic associated with injection-site reactions (7.98%, ROR = 8.17, 95% CI: 7.98, 8.37). Discussion/Conclusion: This is the first large-scale comparative analysis of the AE profiles of dupilumab, omalizumab, and mepolizumab. Our data suggest possible relations between dupilumab and ophthalmologic and injection-site AEs. Omalizumab was the only biologic with a positive anaphylaxis signal. This FAERS investigation suggests important AE differences among these biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Head and Neck Surgery at the University of North Carolina, Chapel Hill, North Carolina, USA.
Förderung
- NCATS NIH HHS
Zitieren
APA
Stack, T. J., Kim, S., Lamb, M. M., Mohammad, I., Zeatoun, A., Lopez, E., Klatt-Cromwell, C., Thorp, B. D., Ebert, C. S., Senior, B. A., Kimple, A. J., & Alicea, D. (2023). Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System. ORL. https://doi.org/10.1159/000534545
Vancouver
Stack TJ, Kim S, Lamb MM, Mohammad I, Zeatoun A, Lopez E, et al. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System. ORL. 2023. doi:10.1159/000534545
BibTeX
@article{Stack2023,
author = {Stack, Taylor J and Kim, Sulgi and Lamb, Meredith M and Mohammad, Ibtisam and Zeatoun, Abdullah and Lopez, Erin and Klatt-Cromwell, Cristine and Thorp, Brian D and Ebert, Charles S and Senior, Brent A and Kimple, Adam J and Alicea, Daniel},
title = {Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System},
journal = {ORL},
year = {2023},
doi = {10.1159/000534545}
}
EUVIMED